Showing 4961-4970 of 5570 results for "".
- Curology Launches Online Service For Customized Prescription Skincarehttps://practicaldermatology.com/news/curology-launches-online-service-for-customized-prescription-skincare/2458862/Curology launched a first-of-its-kind online service that offers customized prescription creams for acne and anti-aging. Founded by dermatologist Dr. David Lortscher, Curology partners patients with licensed healthcare professionals and custom-formulates medications at its laboratory in San Diego
- Novan's SB204 Demonstrates Positive Phase 2b Clinical Trial Results for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/novans-sb204-demonstrates-positive-phase-2b-clinical-trial-results-for-the-treatment-of-acne-vulgaris/2458863/Novan Therapeutics topical nitric oxide drug candidate SB204 for the treatment of acne vulgaris, demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and
- DermTube Offers Video Coverage of NewDerm Live Meetinghttps://practicaldermatology.com/news/dermtube-offers-video-coverage-of-newderm-live-meeting/2458865/NewDerm LIVE, a new meeting for dermatologists just starting out in practice—as well as those not so new to practice—has brought a unique meeting format into the dermatology space. The meeting, supported by the publishers of Practical Dermatology® magazine and NewDerm
- 100,000 Join the ASPIRE Galderma Rewards Loyalty Program in First 90 dayshttps://practicaldermatology.com/news/100000-join-the-aspire-galderma-rewards-loyalty-program-in-the-first-90-days/2458867/Galderma’s ASPIRE Rewards program has enrolled 100,000 consumers since its launch on May 1, 2015. ASPIRE Galderma Rewards is a new loyalty program connecting US consumers and healthcare professionals using the Galderma family of aesthetic products. The vision of the Galderma a
- Suneva Medical: Bellafill Study is Largest, Longest Post-market Clinical Evaluation of Dermal Fillerhttps://practicaldermatology.com/news/suneva-medical-bellafill-study-is-largest-longest-post-market-clinical-evaluation-of-dermal-filler/2458874/Billed as the largest and longest post-market clinical evaluation of a dermal filler, a new study reported by Suneva Medical shows high levels of patient satisfaction and favorable safety outcomes with Bellafill five-years post-treatment. With an 87 percent retention rate, the study showed that a
- FDA Issues Consumer Update about Injectable Skin Lightening Productshttps://practicaldermatology.com/news/fda-issues-consumer-update-about-injectable-skin-lightening-products/2458879/A consumer update from the FDA warns that injectable skin lightening products are unapproved, untested drugs that could potentially cause harm. The FDA adds that it has not approved any injectable drugs for skin whitening or lightening. “These products pose a potentially significant
- FDA Warns of Severe Adverse Events with Application of Picato (ingenol mebutate) Gel; Requires Label Changeshttps://practicaldermatology.com/news/fda-warns-of-severe-adverse-events-with-application-of-picato-ingenol-mebutate-gel-requires-label-changes/2458878/The FDA released a Drug Safety Communication to warn about reports of severe allergic reactions and herpes zoster (shingles) associated with the use of Picato gel (ingenol mebutate), which is approved to treat actinic keratosis. The FDA said it also received reports of cases involving sev
- ASDS Survey Finds Consumers Prefer Its Membershttps://practicaldermatology.com/news/asds-survey-finds-consumers-prefer-its-members/2458882/The 2015 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ratings for 10 specific procedures – shows the majority of respondents in eight of 10 categories who had visited a de
- Genentech Initiates Phase III Trial of Rituximab in Pemphigus Vulgarishttps://practicaldermatology.com/news/genentech-initiates-phase-iii-trial-of-rituximab-in-pemphigus-vulgaris/2458885/Genentech has initiated a Phase III clinical trial investigating the use of Rituxan (rituximab) in patients with pemphigus vulgaris (PV). The aim of the PEMPHIX study is to determin
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to cura